The University Of Texas MD Anderson Cancer Center And Myriad Genetics Announce A 5-Year Strategic Alliance To Accelerate The Clinical Evaluation And Development Of Myriad's Molecular Residual Disease Assay
The University Of Texas MD Anderson Cancer Center And Myriad Genetics Announce A 5-Year Strategic Alliance To Accelerate The Clinical Evaluation And Development Of Myriad's Molecular Residual Disease Assay
德克萨斯大学MD安德森癌症中心与万基遗传宣布建立为期5年的战略联盟，以加速万基的分子残留病检测的临床评估和开发。
The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular residual disease (MRD) assay.
德克萨斯大学MD安德森癌症中心与万基遗传公司今天宣布建立五年战略联盟，以加速万基的分子残留病（MRD）检测的临床评估和开发。
This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad's Precise MRD.
这一战略联盟将万基遗传的长期肿瘤诊断经验与MD安德森的临床和转化研究专业知识相结合，以创建一系列研究，以评估万基的精确MRD的临床有效性和实用性。
资讯热榜
更新时间